Brain Shuttle (Bp42230) A Study To Test The Safety And Effect Of The Study Drug At Different Dose Levels, Determine How Well It Is Tolerated, And Measure How The Body Absorbs And Distributes The Study Drug
Posted Date: Dec 14, 2022
- Investigator: Lawrence Goldstick
- Specialties: Multiple Sclerosis, Neurology
- Type of Study: Drug
The Study Drug (R07121932) combines an antibody with a "brain shuttle" molecule, which delivers it to the brain. The purpose of this study is to test the safety of the study drug at different dose levels; determine how well it is tolerated by you and other participants; measure how the body absorbs, distributes, and gets ride of it (this is called "pharmacokinetics" [PK]); and find out what effects, good or bad, the Study Drug has on you.
Criteria:
Patients With Multiple Sclerosis Between The Ages Of 18 And 55 Who Have Not Had Ocrevus, Rituximab Or Kesimpta In The Last Year.
Keywords:
Ms, Multiple Sclerosis
For More Information:
Mikayla Hoeferlin
937-535-5012
hoefermj@ucmail.uc.edu